Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Atara Biotherapeutics, Inc is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Atara Biotherapeutics employs 429 staff and has a market cap (total outstanding shares value) of USD$1.8 billion.
|Latest market close||USD$19.53|
|52-week range||USD$4.52 - USD$26.1|
|50-day moving average||USD$21.9752|
|200-day moving average||USD$15.4382|
|Wall St. target price||USD$32.89|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-6.071|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||-1.83%|
|1 month (2020-12-18)||-9.79%|
|3 months (2020-10-19)||41.83%|
|6 months (2020-07-17)||42.87%|
|1 year (2020-01-17)||29.94%|
|2 years (2019-01-18)||-47.57%|
|3 years (2018-01-18)||27.5|
|5 years (2016-01-15)||20.88|
|Gross profit TTM||USD$0|
|Return on assets TTM||-49.83%|
|Return on equity TTM||-90.37%|
|Market capitalisation||USD$1.8 billion|
TTM: trailing 12 months
There are currently 12.5 million Atara Biotherapeutics shares held short by investors – that's known as Atara Biotherapeutics's "short interest". This figure is 0.9% up from 12.3 million last month.
There are a few different ways that this level of interest in shorting Atara Biotherapeutics shares can be evaluated.
Atara Biotherapeutics's "short interest ratio" (SIR) is the quantity of Atara Biotherapeutics shares currently shorted divided by the average quantity of Atara Biotherapeutics shares traded daily (recently around 1.2 million). Atara Biotherapeutics's SIR currently stands at 10.83. In other words for every 100,000 Atara Biotherapeutics shares traded daily on the market, roughly 10830 shares are currently held short.
However Atara Biotherapeutics's short interest can also be evaluated against the total number of Atara Biotherapeutics shares, or, against the total number of tradable Atara Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atara Biotherapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Atara Biotherapeutics shares in existence, roughly 150 shares are currently held short) or 0.1716% of the tradable shares (for every 100,000 tradable Atara Biotherapeutics shares, roughly 172 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Atara Biotherapeutics.
Find out more about how you can short Atara Biotherapeutics stock.
We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $4.52 up to $26.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 2.769. This would suggest that Atara Biotherapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was founded in 2012 and is headquartered in South San Francisco, California.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.